Institute for Breathing and Sleep, Austin Hospital, Heidelberg, VIC, Australia.
Department of Respiratory and Sleep Medicine, Austin Hospital, Heidelberg, VIC, Australia.
BMC Pulm Med. 2024 Oct 10;24(1):501. doi: 10.1186/s12890-024-03319-9.
Pulmonary rehabilitation (PR) is widely recommended for short-term benefits in chronic respiratory diseases, yet long-term outcomes remain uncertain. This retrospective cohort study addresses this gap, comparing 20-year mortality rates between PR participants and matched controls, and hypothesizing that the short-term benefits of PR contribute to improved long-term survival.
The 20-year mortality of stable chronic respiratory patients who participated in an outpatient PR program was compared with a matched control group based on the type of lung disease. Demographic and clinical variables, and the dates of deaths, were extracted and compared between two groups with two sample t-test and chi-square tests. Kaplan-Meier plots and Cox regression analyses were employed to evaluate survival differences.
Between 2000 and 2002, 238 individuals enrolled in a pulmonary rehabilitation (PR) program (58% male, mean age ± SD: 69 ± 8 years, mean FEV% predicted ± SD: 46 ± 21%). An equal number of people with comparable lung disease were selected as controls (88% COPD, 5% ILD). Controls had lower FEV% predicted values (mean ± SD: 39 ± 17%, P < 0.001), smoked more (mean ± SD: 48 ± 35 pack-years, P = 0.032), and no differences in age, BMI, sex, and Index of Relative Socio-economic Advantage and Disadvantage (IRSAD). Median (IQR) follow-up time was 68 months (34-123), with 371 (78%) deaths. Univariable (HR = 1.71, p < 0.001) and multivariable (HR = 1.64, p < 0.001) Cox regression found higher mortality risk in controls. Subgroup analysis for COPD replicated these findings (HR = 1.70, P < 0.001).
Despite some methodological limitations, our study suggests that clinically stable patients with chronic respiratory disease who undertake PR may have lower mortality than matched controls.
Retrospectively registered.
肺康复(PR)被广泛推荐用于慢性呼吸系统疾病的短期获益,但长期结果仍不确定。这项回顾性队列研究旨在填补这一空白,比较 PR 参与者和匹配对照组的 20 年死亡率,并假设 PR 的短期获益有助于改善长期生存。
根据肺部疾病类型,比较参加门诊 PR 计划的稳定慢性呼吸系统患者的 20 年死亡率与匹配对照组。提取并比较两组的人口统计学和临床变量以及死亡日期,并通过两样本 t 检验和卡方检验进行比较。采用 Kaplan-Meier 图和 Cox 回归分析评估生存差异。
在 2000 年至 2002 年间,238 名患者参加了肺康复(PR)计划(58%为男性,平均年龄±标准差:69±8 岁,平均 FEV%预计值±标准差:46±21%)。选择了相同数量具有类似肺部疾病的人作为对照组(88%为 COPD,5%为 ILD)。对照组的 FEV%预计值较低(平均值±标准差:39±17%,P<0.001),吸烟更多(平均值±标准差:48±35 包年,P=0.032),年龄、BMI、性别和相对社会经济优势和劣势指数(IRSAD)无差异。中位(IQR)随访时间为 68 个月(34-123),371 人(78%)死亡。单变量(HR=1.71,p<0.001)和多变量(HR=1.64,p<0.001)Cox 回归发现对照组的死亡率更高。COPD 的亚组分析复制了这些发现(HR=1.70,P<0.001)。
尽管存在一些方法学限制,但我们的研究表明,接受 PR 的患有慢性呼吸系统疾病的临床稳定患者的死亡率可能低于匹配对照组。
回顾性注册。